The Greens Health Centre

Tirzepatide (Mounjaro): A new treatment option for managing obesity

New community-based weight management services are being developed across the Black Country to support safe and effective access to tirzepatide (Mounjaro), a medication that can help with weight loss and related health conditions.

We anticipate these will be available via primary care from September2025.

As part of our phased approach, the first group of patients who may be eligible will include those who:

·                    Have a BMI of 40 or more (or 37.5 for people from minority ethnic backgrounds)

·                    And have obstructive sleep apnoea on CPAP (or where CPAP is not tolerated)

And have at least three of the following long-term conditions:

·                    Type 2 diabetes

·                    High blood pressure (hypertension)

·                    Cardiovascular disease

·                    Dyslipidaemia

Other patients who meet the broader NHS criteria (BMI ≥ 40 and four or more related health conditions) may become eligible in later stages.

Please do not contact the practice about tirzepatide at this time. If you are eligible, you will be contacted by your practice.

Weight management services are locally commissioned by the Black Country Integrated Care Board, you can find out more information on Access to Tirzepatide (Mounjaro) for Weight Management in the Black Country here.